View Financial HealthSkinvisible 配当と自社株買い配当金 基準チェック /06Skinvisible配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 01Skinvisible, Inc. announced delayed annual 10-K filingOn 03/31/2025, Skinvisible, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Skinvisible, Inc. announced delayed 10-Q filingOn 11/14/2024, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Skinvisible, Inc. announced delayed 10-Q filingOn 08/14/2024, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 10Skinvisible Pharmaceuticals, Inc. Unveils Promising Data on Transdermal Obesity FormulationsSkinvisible Pharmaceuticals, Inc. announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose- controlling drugs) including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare technology; a polymer delivery vehicle that does not require a patch or needles. The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and other glucose-controlling agents. The Company has been developing topical formulations to enable transdermal absorption of these drugs, allowing for sustained release into the bloodstream. The results are compelling: Franz Cell diffusion studies demonstrated up to 69% penetration over six hours for the GLP-1 drug tested; For the CB-1 antagonists formulated with Invisicare, a 62% penetration rate was achieved over the same time period; In addition to these high penetration rates, these studies demonstrate that Invisicare formulations have the ability to provide sustained drug delivery over time. Data showed an average drug release of approximately 10% per hour. Building on this breakthrough, Skinvisible is confident that its proprietary technology can be applied to a broader range of GLP-1 agonists and CB-1 receptor antagonists with a molecular mass that permits transdermal penetration. This development opens up exciting possibilities for expanding the company's portfolio of obesity-targeting formulations.お知らせ • Jun 06Skinvisible, Inc. announced that it has received $0.035 million in fundingSkinvisible, Inc. announced a private placement that it has issued a total of 350,000 units to accredited investors, where each unit was priced at $0.10 per unit for the gross proceeds of $35,000 on June 4, 2024. Each unit consists of one share of common stock in the company and a warrant to purchase one-half of one share of common stock in the company, exercisable for one year from issuance with an exercise price at $0.20 per share.お知らせ • Apr 02Skinvisible, Inc. announced delayed annual 10-K filingOn 04/01/2024, Skinvisible, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Skinvisible, Inc. announced delayed 10-Q filingOn 11/15/2023, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 19Skinvisible, Inc. announced delayed 10-Q filingOn 05/18/2021, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 31Skinvisible, Inc. announced delayed annual 10-K filingOn 03/29/2021, Skinvisible, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Skinvisible, Inc. announced delayed 10-Q filingOn 11/16/2020, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Skinvisible, Inc. announced delayed 10-Q filingOn 08/14/2020, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 30Skinvisible, Inc. announced delayed 10-Q filingOn 06/29/2020, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: SKVIの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SKVIの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Skinvisible 配当利回り対市場SKVI 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SKVI)n/a市場下位25% (US)1.4%市場トップ25% (US)4.1%業界平均 (Personal Products)3.1%アナリスト予想 (SKVI) (最長3年)n/a注目すべき配当: SKVIは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SKVIは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SKVIの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SKVIが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/13 02:25終値2026/06/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Skinvisible, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Siddharth RajeevFundamental Research Corp.
お知らせ • Apr 01Skinvisible, Inc. announced delayed annual 10-K filingOn 03/31/2025, Skinvisible, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Skinvisible, Inc. announced delayed 10-Q filingOn 11/14/2024, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Skinvisible, Inc. announced delayed 10-Q filingOn 08/14/2024, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 10Skinvisible Pharmaceuticals, Inc. Unveils Promising Data on Transdermal Obesity FormulationsSkinvisible Pharmaceuticals, Inc. announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose- controlling drugs) including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare technology; a polymer delivery vehicle that does not require a patch or needles. The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and other glucose-controlling agents. The Company has been developing topical formulations to enable transdermal absorption of these drugs, allowing for sustained release into the bloodstream. The results are compelling: Franz Cell diffusion studies demonstrated up to 69% penetration over six hours for the GLP-1 drug tested; For the CB-1 antagonists formulated with Invisicare, a 62% penetration rate was achieved over the same time period; In addition to these high penetration rates, these studies demonstrate that Invisicare formulations have the ability to provide sustained drug delivery over time. Data showed an average drug release of approximately 10% per hour. Building on this breakthrough, Skinvisible is confident that its proprietary technology can be applied to a broader range of GLP-1 agonists and CB-1 receptor antagonists with a molecular mass that permits transdermal penetration. This development opens up exciting possibilities for expanding the company's portfolio of obesity-targeting formulations.
お知らせ • Jun 06Skinvisible, Inc. announced that it has received $0.035 million in fundingSkinvisible, Inc. announced a private placement that it has issued a total of 350,000 units to accredited investors, where each unit was priced at $0.10 per unit for the gross proceeds of $35,000 on June 4, 2024. Each unit consists of one share of common stock in the company and a warrant to purchase one-half of one share of common stock in the company, exercisable for one year from issuance with an exercise price at $0.20 per share.
お知らせ • Apr 02Skinvisible, Inc. announced delayed annual 10-K filingOn 04/01/2024, Skinvisible, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Skinvisible, Inc. announced delayed 10-Q filingOn 11/15/2023, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 19Skinvisible, Inc. announced delayed 10-Q filingOn 05/18/2021, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 31Skinvisible, Inc. announced delayed annual 10-K filingOn 03/29/2021, Skinvisible, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Skinvisible, Inc. announced delayed 10-Q filingOn 11/16/2020, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Skinvisible, Inc. announced delayed 10-Q filingOn 08/14/2020, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 30Skinvisible, Inc. announced delayed 10-Q filingOn 06/29/2020, Skinvisible, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.